Orchid Pharma Limited announced its financial results for the fourth quarter and full fiscal year ended March 31, 2026. The company reported a consolidated revenue of ₹811 crore for FY26, a decrease of 12% from FY25’s ₹922 crore. EBITDA for FY26 stood at ₹101 crore, down 36% year-on-year. Profit After Tax (PAT) for the fiscal year was ₹45 crore, a significant reduction from ₹106 crore in FY25.
Orchid Pharma Financial Highlights: FY26
Orchid Pharma Limited has released its financial performance for the fiscal year ended March 31, 2026 (FY26) and the fourth quarter (Q4 FY26). The standalone financial results indicate a mixed performance, with a slight increase in Q4 revenue but a notable decrease in full-year revenue and profitability.
Standalone Performance: FY26 vs FY25
For the full fiscal year FY26, Orchid Pharma reported a Revenue from Operations of ₹811 crore, which represents a -12% change compared to ₹922 crore in FY25. Other Income saw a substantial increase of +72%, reaching ₹55 crore from ₹32 crore in the previous year. However, Cost of Goods Sold (COGS) rose to ₹526 crore from ₹544 crore. Employee expenses increased slightly by +2% to ₹88 crore, while Other Expenses decreased by -10% to ₹152 crore.
EBITDA for FY26 was ₹101 crore, a significant decrease of -36% from FY25’s ₹156 crore. The EBITDA margin as a percentage of sales was 12% in FY26, down from 17% in FY25. Interest expenses saw a -13% reduction, totaling ₹13 crore. Depreciation remained relatively stable at ₹36 crore. Exceptional items for FY26 were negative ₹6 crore, compared to ₹0 in FY25. Consequently, Profit After Tax (PAT) for FY26 stood at ₹45 crore, a sharp decline from ₹106 crore in FY25.
Standalone Performance: Q4 FY26 vs Q4 FY25
In the fourth quarter of FY26 (Q4-26), the company reported a Revenue from Operations of ₹238 crore, showing a marginal +0% change from ₹237 crore in Q4-25. Other Income surged by +117% to ₹13 crore from ₹6 crore. COGS increased to ₹151 crore from ₹138 crore. Employee Expenses decreased by -9% to ₹20 crore, and Other Expenses fell by -12% to ₹38 crore.
EBITDA for Q4-26 was ₹42 crore, a +5% increase from ₹40 crore in Q4-25. The EBITDA margin improved slightly to 18% from 17%. Interest expenses decreased by -25% to ₹3 crore. Depreciation was stable at ₹9 crore. Exceptional items in Q4-26 were ₹1 crore, up from ₹0 in the prior year. Profit After Tax (PAT) for Q4-26 was ₹30 crore, an increase from ₹28 crore in Q4-25.
Key Financial Charts
The presentation also includes visual representations of key financial metrics:
- Total Revenue: Shows a slight increase from Q4 FY25 to Q4 FY26, but a decrease from FY25 to FY26.
- EBITDA: Indicates growth in Q4 FY26 compared to Q4 FY25, and a significant drop from FY25 to FY26.
- PAT: Demonstrates an increase in Q4 FY26 over Q4 FY25, but a substantial decrease for the full year FY26 compared to FY25.
- Gross Margin: Decreased from 42% in Q4 FY25 to 36% in Q4 FY26, and from 41% in FY25 to 35% in FY26.
- EBITDA Margin: Showed improvement in Q4 FY26 (17%) compared to Q4 FY25 (16%), but a decrease from 16% in FY25 to 12% in FY26.
Strategic Pillars and Future Outlook
The company’s strategic direction is focused on building a differentiated, long-term position in critical antibiotics. Key initiatives include the development of an integrated anti-infectives model with multiple value pools, leveraging merger synergies for scaling strategies, and continued execution in areas like 7ACA + Downstream Integration, Cefiderocol Access Project, FDF Capability & Filings, and R&D Pipeline development.
The company emphasizes its transition from a turnaround phase to platform creation, aiming to establish itself as a key innovator in the antibiotics market. Investment priorities highlight significant allocations towards 7ACA + Downstream Integration (₹750 Cr), Cefiderocol Access Project (₹200 Cr), FDF Capability & Filings (₹50 Cr), and R&D / Pipeline (₹15 Cr).
Source: BSE
